---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-26-008347"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2026-09-14T21:22:12+00:00"
generated_at: "2026-09-14T21:24:04.750489+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q3 revenue up ~$0.4M YoY; net loss narrows to $14K

## Summary
- Q3 (ended July 31, 2026) revenue ~$2.3M, up ~$0.4M YoY; nine-month revenue ~$7.3M, up ~$0.5M YoY.
- Q3 net loss of $14K, an ~$190K improvement YoY; nine-month net income ~$252K, up ~$352K YoY.
- CEO Victor Sanchez credits client relationships and specialized compliance capabilities for improved performance.

## SEC filing metadata
- accession: 0001654954-26-008347
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2026-09-14T21:22:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495426008347/0001654954-26-008347-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495426008347/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-26-008347
- JSON: https://secwatch.observer/filing/0001654954-26-008347.json
- Plain text: https://secwatch.observer/filing/0001654954-26-008347.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.